Opsona Therapeutics

Opsona Therapeutics
Website www.opsona.com

Opsona Therapeutics is a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.[1][2][3]

Based in Ireland, Opsona is a spin-out from Trinity College Dublin (TCD).[4] Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field.[5]

Opsona's research is primarily focused on the role of Toll-like receptors (TLRs) and TLR signalling in human innate immunity. The company was founded in 2004 by three immunologists:

Opsona's main investors are international and life-science focused:

  • Inventages Venture Capital (Bahamas)[9]
  • Seroba Bioventures (Ireland)
  • GenenFund (United States)
  • Enterprise Ireland (Ireland)[10]

References

  1. ↑ "Ireland's got talent". Retrieved 27 February 2018.
  2. ↑ "Sunday Business Post article". Retrieved 27 February 2018.
  3. ↑ "Opsona Therapeutics Limited: Private Company Information - Bloomberg". investing.businessweek.com. Retrieved 27 February 2018.
  4. ↑ "Emerging finalist: Mark Heffernan Opsona Therapeutics". Retrieved 27 February 2018.
  5. ↑ Times Higher Educational Supplement - QS World University Rankings 2007
  6. ↑ "Trinity team makes vaccine discovery". 4 May 2009. Retrieved 27 February 2018.
  7. ↑ Dublin, bbutler@tcd.ie, Trinity College. "Kingston Mills - Research : School of Biochemistry and Immunology : Trinity College Dublin, the University of Dublin, Ireland". www.tcd.ie. Retrieved 27 February 2018.
  8. ↑ "Article on the Trinity College Dublin website". Retrieved 27 February 2018.
  9. ↑ "Opsona Therapeutics Closes EUR18M Funding - FierceBiotech". www.fiercebiotech.com. Retrieved 27 February 2018.
  10. ↑ "PR Newswire article". Retrieved 27 February 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.